NHTA
Consultancy focused on market access, health technology assessment (HTA), health economics and evidence generation for the Nordic region. Services include strategic market access planning, HTA submission support, health-economic modelling, real-world evidence studies using Nordic registry data, and payer/HTA stakeholder engagement. Operates offices in Copenhagen and Stockholm and reports GDPR/data-protection processes for client data.
Industries
Nr. of Employees
small (1-50)
NHTA
Nelson Mandelas Allé 14, 2450 Copenhagen SV, Denmark
Products
Market Access
Provides strategies to navigate complex market access environments tailored to different technologies, regions, and healthcare landscapes.
Health Technology Assessment (HTA) Submissions
Supports the preparation and development of HTA submissions to improve the likelihood of reimbursement success.
Health Economics
Develops health economic models and analyses to demonstrate the value of healthcare technologies.
Evidence Generation & Real-World Evidence (RWE)
Designs and implements evidence generation strategies including real-world data studies to support regulatory and market access needs.
Market Access
Provides strategies to navigate complex market access environments tailored to different technologies, regions, and healthcare landscapes.
Health Technology Assessment (HTA) Submissions
Supports the preparation and development of HTA submissions to improve the likelihood of reimbursement success.
Health Economics
Develops health economic models and analyses to demonstrate the value of healthcare technologies.
Evidence Generation & Real-World Evidence (RWE)
Designs and implements evidence generation strategies including real-world data studies to support regulatory and market access needs.
Services
Strategic market access planning and country-specific access strategies for Nordic reimbursement and procurement environments.
Preparation and optimisation of HTA submissions for Nordic, UK and EU jurisdictions including dossier drafting and value story development.
Development of global and local economic models, bespoke model adaptations, and stakeholder-facing implementations.
Design and conduct of RWE studies, external control arms, MAICs and registry-data analyses to support HTA resubmissions and reduce uncertainty.
Creation of dossier materials and living documents to track HTA submissions and manage payer objections across markets.
Strategic market access planning and country-specific access strategies for Nordic reimbursement and procurement environments.
Preparation and optimisation of HTA submissions for Nordic, UK and EU jurisdictions including dossier drafting and value story development.
Development of global and local economic models, bespoke model adaptations, and stakeholder-facing implementations.
Design and conduct of RWE studies, external control arms, MAICs and registry-data analyses to support HTA resubmissions and reduce uncertainty.
Creation of dossier materials and living documents to track HTA submissions and manage payer objections across markets.
Expertise Areas
- Market access strategy for Nordic markets
- Health Technology Assessment (HTA) submissions
- Health-economic modelling and cost-effectiveness analysis
- Real-world evidence and registry-based studies
Key Technologies
- R-Shiny interactive modelling
- Matching-adjusted indirect comparison (MAIC)
- External control arm construction
- Registry-based real-world data analysis
News & Updates
Article discussing factors that influence NICE recommendations for medical devices.
Overview of barriers to scaling value-based procurement in MedTech and key literature on the topic.
Announcement of partnership/participation in ENCePP and conduct of PASS and regulatory-RWE studies with Nordic data.
Summary of a panel discussion on the expected impact of the EU Joint Clinical Assessment (JCA) on Sweden’s HTA processes and access timelines.
Insight article examining how HTA agencies handle uncertainty from short trial follow-up and the use of managed entry agreements.
Announcement of internal promotion from Senior Consultant to Principal Consultant.
Article discussing factors that influence NICE recommendations for medical devices.
Overview of barriers to scaling value-based procurement in MedTech and key literature on the topic.
Announcement of partnership/participation in ENCePP and conduct of PASS and regulatory-RWE studies with Nordic data.
Summary of a panel discussion on the expected impact of the EU Joint Clinical Assessment (JCA) on Sweden’s HTA processes and access timelines.
Insight article examining how HTA agencies handle uncertainty from short trial follow-up and the use of managed entry agreements.
Announcement of internal promotion from Senior Consultant to Principal Consultant.